Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients

Biochimica et Biophysica Acta - Biomembranes

Volumn 1414, Issue 1-2, 1998, Pages 188-204

  Fenske, David B ^a   Wong, Kim F ^a   Maurer, Elisabeth ^a   Maurer, Norbert ^a   Leenhouts, Johanna M ^a   Boman, Nancy ^b   Amankwa, Lawrence ^b   Cullis, Pieter R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Inex Pharmaceuticals Corporation   (Canada)

Author keywords

A23187; Ciprofloxacin; Divalent cation; Drug loading; Ionophore; Manganese; Nigericin; pH gradient; Vincristine

Indexed keywords

CALCIMYCIN; CIPROFLOXACIN; DIVALENT CATION; IONOPHORE; MANGANESE; NIGERICIN; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENCAPSULATION; MEMBRANE VESICLE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL;

ANIMALS; BLOOD; CALCIMYCIN; CIPROFLOXACIN; DEXTRANS; DRUG CARRIERS; EDETIC ACID; GELS; HYDROGEN-ION CONCENTRATION; ION TRANSPORT; IONOPHORES; LIPOSOMES; MANGANESE; MICE; NIGERICIN; POTASSIUM; VINCRISTINE;

EID: 0032508857     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(98)00166-7     Document Type: Article

References (66)

1. [1] P.R. Cullis, M.J. Hope, M.B. Bally, T.D. Madden, L.D. Mayer, D.B. Fenske, Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles, Biochim. Biophys. Acta 1331 (1997) 187-211.
2. [2] L.D. Mayer, L.C.L. Tai, D.S.C. Ko, D. Masin, R.S. Ginsberg, P.R. Cullis, M.B. Bally, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res. 49 (1989) 5922-5930.
3. [3] L.D. Mayer, M.B. Bally, P.R. Cullis, S.L. Wilson, J.T. Emerman, Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor, Cancer Lett. 53 (1990) 183-190.
4. [4] L.D. Mayer, M.B. Bally, P.R. Cullis, Strategies for optimizing liposomal doxorubicin, J. Liposome Res. 1 (1990) 463-480.
5. [5] P.R. Harrigan, K.F. Wong, T.E. Redelmeier, J.J. Wheeler, P.R. Cullis, Accumulation of doxorubicin and other lipophilic amines Into large unilamellar vesicles in response to transmembrane pH gradients, Biochim. Biophys. Acta 1149 (1993) 329-338.
6. [6] N.L. Boman, L.D. Mayer, P.R. Cullis, Optimization of the retention properties of vincristine in liposomal systems, Biochim. Biophys. Acta 1152 (1993) 253-258.
7. [7] N.L. Boman, D. Masin, L.D. Mayer, P.R. Cullis, M.B. Bally, Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors, Cancer Res. 54 (1994) 2830-2833.
8. [8] N.L. Boman, M.B. Bally, P.R. Cullis, L.D. Mayer, M.S. Webb, Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumour efficacy, J. Liposome Res. 5 (1995) 523-541.
9. [9] A.J. Coukell, C.M. Spencer, Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 53 (1997) 520-538.
10. [10] F.M. Muggia, J.D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tam, L. Roman, B. Uziely, L. Muderspach, A. Garcia, A. Burnett, F.A. Greco, C.P. Morrow, L.J. Paradiso, L.J. Liang, Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation, J. Clin. Oncol. 15 (1997) 987-993.
11. [11] R. Janknegt, Liposomal formulations of cytotoxic drugs, Supportive Care Cancer 4 (1996) 298-304.
12. [12] A. Chonn, P.R. Cullis, Recent advances in liposomal drug delivery systems, Curr. Opin. Biotechnol. 6 (1995) 698-708.
13. [13] N.L. Boman, P.R. Cullis, M.B. Bally, L.D. Mayer, Pre-clinical and clinical activity of liposomal doxorubicin, in: P.N. Shek (Ed.), Liposomes in Biomedical Applications, Harwood Academic Publishers, Singapore, 1995, pp. 85-103.
14. [14] M.J. Hope, K.F. Wong, Liposomal formulation of ciprofloxacin, in: P.N. Shek (Ed.), Liposomes in Biomedical Applications, Harwood Academic Publishers, Singapore, 1995, pp. 121-134.
15. [15] D.D. Lasic, P.M. Frederik, M.C.A. Stuart, Y. Barenholz, T.J. McIntosh, Gelation of liposome interior. A novel method for drug encapsulation, FEBS Lett. 312 (1992) 255-258.
16. [16] G. Haran, R. Cohen, L.K. Bar, Y. Barenholz, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta 1151 (1993) 201-215.
17. [17] D.D. Lasic, B. Ceh, M.C.A. Stuart, L. Guo, P.M. Frederik, Y. Barenholz, Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery, Biochim. Biophys. Acta 1239 (1995) 145-156.
18. [18] E. Maurer-Spurej, K.F. Wong, N. Maurer, D.B. Fenske, P.R. Cullis, Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients, (1998) manuscript submitted.
19. [19] D.W. Deamer, R.C. Prince, A.R. Crofts, The response of fluorescent amines to pH gradients across liposome membranes, Biochim. Biophys. Acta 274 (1972) 323-335.
20. [20] M.J. Hope, M.B. Bally, G. Webb, P.R. Cullis, Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential, Biochim. Biophys. Acta 812 (1985) 55-65.
21. [21] U. Pick, Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures, Arch. Biochem. Biophys. 212 (1981) 186-194.
22. [22] T.D. Madden, P.R. Harrigan, L.C. Tai, M.B. Bally, L.D. Mayer, T.E. Redelmeier, H.C. Loughrey, C.P.S. Tilcock, L.W. Reinish, P.R. Cullis, The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey, Chem. Phys. Lipids 53 (1990) 37-46.
23. [23] C.H. Fiske, Y. Subbarow, The colorimetric determination of phosphorus, J. Biol. Chem. 66 (1925) 375-400.
24. [24] V.L. Di Ninno, J.W. Cherwonogrodzky, J.P. Wong, Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of BALB/c mice against Francisella tularensis, J. Infect. Dis. 168 (1993) 793-794.
25. [25] S.K. Carter, R.B. Livingston, Plant products in cancer chemotherapy, Cancer Treat. Rep. 60 (1976) 1141-1156.
26. [26] S.M. Sieber, J.A.R. Mead, R.H. Adamson, Pharmacology of antitumour agents from higher plants, Cancer Treat. Rep. 60 (1976) 1127-1139.
27. [27] M.S. Webb, T.O. Harasym, D. Masin, M.B. Bally, L.D. Mayer, Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models, Br. J. Cancer 72 (1995) 896-904.
28. [28] B.C. Pressman, Biological applications of ionophores, Annu. Rev. Biochem. 45 (1976) 501-530.
29. 2+ transport properties of ionophores A23187, ionomycin, and 4-BrA23187 in a well defined model system, Biophys. J. 66 (1994) 1678-1693.
30. 2+ transport catalyzed by ionophores A23187, 4-BrA23187, and ionomycin suggest problems with common applications of these compounds in biological systems, Biophys. J. 69 (1995) 2350-2363.
31. [31] P.R. Harrigan, M.J. Hope, T.E. Redelmeier, P.R. Cullis, Determination of transmembrane pH gradients and membrane potentials in liposomes, Biophys. J. 63 (1992) 1336-1345.
32. 2+, Biochemistry 35 (1996) 13817-13825.
33. +-exchange on the bilayer lipid membrane, Biochim. Biophys. Acta 1027 (1990) 295-300.
34. [34] Y.N. Antonenko, L.S. Yaguzhinsky, Biol. Membr. (Russian) 5 (1988) 718-728.
35. 2+ into large unilamellar vesicles in response to transmembrane pH gradients, Mol. Membr. Biol. 11 (1994) 151-158.
36. [36] A.H. Caswell, B.C. Pressman, Kinetics of transport of divalent cations across sarcoplasmic reticulum vesicles by ionophores, Biochem. Biophys. Res. Commun. 49 (1972) 292-298.
37. [37] J.S. Puskin, T.E. Gunter, Electron paramagnetic resonance of copper ion and manganese ion complexes with the ionophore A23187, Biochemistry 14 (1975) 187-191.
38. + transport in mitochondria mediated by A23187, Biochemistry 15 (1976) 935-943.
39. [39] C.J. Chapman, A.K. Puri, R.W. Taylor, R. Pfeiffer, General features in the stoichiometry and stability of ionophore A23187-cation complexes in homogeneous solution, Arch. Biochem. Biophys. 281 (1990) 44-57.
40. [40] J. Wulf, W.G. Pohl, Calcium ion-flux across phosphatidylcholine membranes mediated by ionophore A23187, Biochim. Biophys. Acta 465 (1977) 471-485.
41. [41] C.J. Chapman, A.K. Puri, R.W. Taylor, R. Pfeiffer, Equilibria between ionophore A23187 and divalent cations: stability of 1:1 complexes in solutions of 80% methanol/water, Biochemistry 26 (1987) 5009-5018.
42. 23Na-nuclear magnetic resonance study of ionophore-mediated cation exchange between two populations of vesicles, Biophys. J. 64 (1993) 1445-1455.
43. [43] J.-F. Tocanne, J. Teissie, Ionization of phospholipids and phospholipid-supported interfacial lateral diffusion of protons in membrane model systems, Biochim. Biophys. Acta 1031 (1990) 111-142.
44. [44] Calbiochem-Novabiochem, Material Safety Data Sheet for A23187, 19 October 1994.
45. [45] T.J. Sobotka, R.E. Brodie, Y. Quander, M. O'Donnell, G.L. West, Neurobehavioral effects of the calcium ionophore A23187, Neurotoxicol. Teratol. 9 (1987) 99-106.
46. [46] P.W. Stengel, P.A. Pechous, S.A. Silbaugh, A23187-induced pulmonary gas trapping and inflammation in the guinea pig, Prostaglandins 3 (1991) 567-577.
47. [47] D. Mergler, Manganese: the controversial metal. At what levels can deleterious effects occur?, Can. J. Neurol. Sci. 23 (1996) 93-94.
48. [48] M. Saric, M. Piasek, Metal exposure studies: role of toxicology and epidemiology in public health policy, Arh. Hig. Rada Toksikol. 48 (1997) 307-317.
49. [49] D. Mergler, M. Baldwin, Early manifestations of manganese neurotoxicity in humans: an update, Environ. Res. 73 (1997) 92-100.
50. [50] Y. Ni, G. Marchal, Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities, Acta Radiol. 38 (1997) 724-731.
51. 2, Acta Radiol. 38 (1997) 740-749.
52. [52] E.R. Wisner, E. Merisko-Liversidge, K. Kellar, R.W. Katzberg, P.H. Karpinski, E.G. Amparo, C. Drake, S.M. Griffey, J.M. Brock, Preclinical evaluation of manganese carbonate particles for magnetic resonance imaging of the liver, Acad. Radiol. 2 (1995) 140-147.
53. [53] D.H. Robinson, U.P. Schmiedl, F.L. Starr, J.A. Nelson, R. Malek, Intravenous manganese-mesoporphyrin as a magnetic resonance imaging contrast agent: an experimental model using VX-2 carcinoma in rabbits, Acad. Radiol. 2 (1995) 43-49.
54. [54] L.D. Mayer, L.C.L. Tai, D.S.C. Ko, D. Masin, R.S. Ginsberg, P.R. Cullis, M.B. Bally, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res. 49 (1989) 5922-5930.
55. [55] J.M.C. Gutteridge, Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of doxorubicin-iron (III) complex, Biochem. Pharmacol. 33 (1984) 1725-1728.
56. [56] J.R.F. Muindi, B.K. Sinha, L. Gianni, C.E. Myers, Hydroxyl radical production and DNA damage induced by anthracycline-iron complex, FEBS Lett. 172 (1984) 226-230.
57. [57] B.B. Hasinoff, Self-reduction of the iron(III)-doxorubicin complex, Free Radic. Biol. Med. 7 (1989) 583-593.
58. [58] F.T. Greenaway, J.C. Dabrowiak, The binding of copper ions to daunomycin and adriamycin, J. Inorg. Biochem. 16 (1982) 91-107.
59. [59] B.B. Hasinoff, J.P. Davey, P.J. O'Brien, The adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper, Xenobiotica 19 (1989) 231-241.
60. [60] E.H. Herman, J. Zhang, B.B. Hasinoff, J.R. Clark Jr., V.J. Ferrans, Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex, J. Mol. Cell. Cardiol. 29 (1997) 2415-2430.
61. [61] N.R. Campbell, M. Kara, B.B. Hasinoff, W.M. Haddara, D.W. McKay, Norfloxacin interaction with antacids and minerals, Br. J. Clin. Pharmacol. 33 (1992) 115-116.
62. [62] M. Kara, B.B. Hasinoff, D.W. McKay, N.R. Campbell, Clinical and chemical interactions between iron preparations and ciprofloxacin, Br. J. Clin. Pharmacol. 31 (1991) 257-261.
63. 3+-doxorubicin complex undergoing self-reduction by its alpha-ketol group, Biochem. Cell Biol. 68 (1990) 1331-1336.
64. [64] R. Bachur, S.L. Gordon, M.V. Gee, Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation, Mol. Pharmacol. 13 (1977) 901-910.
65. [65] J. Bouma, J.H. Beijnen, A. Bult, W.J.M. Underberg, Anthracycline antitumour agents: a review of physicochemical, analytical and stability properties, Pharm. Weekbl. Sci. Edn. 8 (1986) 109-133.
66. [66] J.W. Lown, H. Chen, J.A. Plambeck, Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects, Biochem. Pharmacol. 31 (1982) 575-581.